Background. The manifestations of non-alcoholic fatty liver disease in patients who have undergone pancreatoduodenectomy differ from those associated with obesity-related non-alcoholic fatty liver disease. This study aimed to identify factors that predicted the occurrence of and recovery from non-alcoholic fatty liver disease after pancreatoduodenectomy. Methods. This retrospective study included 120 patients who underwent pancreatoduodenectomy between April 2004 and December 2013. Non-alcoholic fatty liver disease was diagnosed using unenhanced computed tomography as a value of <40 Hounsfield units. Recovery from non-alcoholic fatty liver disease was based on increases in liver computed tomographic attenuation values. Pre-, intra-, and postoperative factors were analyzed using univariate analysis and multivariable logistic regression models.
deficiencies, osteopenia, and liver dysfunction. [11] [12] [13] Although most human organs have functional reserves, loss of exocrine function in the pancreas is clearly proportional to how much of the organ has been resected. A previous study found that malnutrition occurs in patients who have undergone resection of 90% of the pancreas. 14 Furthermore, the frequency of NAFLD is greater after PD than after distal pancreatectomy, 8 but few studies have investigated the effects of PD on pancreatic exocrine function.
NAFLD has become widespread and is associated with the increasing prevalence of obesity. [15] [16] [17] [18] NAFLD after PD, however, has manifestations that differ from NAFLD associated with obesity. 5, 7 Though only a few reports have been published, 4, 5 previous investigations of NAFLD after PD have identified some of the risk factors associated with its development and have determined that pancreatic enzyme replacement therapy provides some benefits. Furthermore, the risk factors are varied, and the effects of the reconstruction methods used were not examined. 5, 7, 9, 10 Moreover, the efficacy of pancreatic enzyme replacement therapy in the prevention of and recovery from NAFLD has not been clarified. This retrospective study had 2 aims, namely, to evaluate previously reported and other potential risk factors for NAFLD after PD and to assess the factors that affect recovery from NAFLD after PD.
METHODS
Patients. Our study included 127 consecutive patients who had undergone conventional PD or pylorus-preserving PD, subtotal stomach-preserving PD that involves dividing the stomach 2-3 cm proximal to the pylorus ring and resecting all of the duodenum, gallbladder, common bile duct, and the head of the pancreas, 19 at Nagoya City University Hospital between April 2004 and December 2013. Until March 2007, the reconstruction procedure was based on the Imanaga method, 20 which involves external drainage of the main pancreatic duct (MPD). In April 2007, the reconstruction procedure was changed to a modified Child method, 21 which involves an end-to-side pancreaticojejunostomy plus a Braun anastomosis, with external drainage of the MPD. We excluded 4 patients who changed hospitals during the early postoperative period and who never underwent postoperative computed tomography (CT) at our institute, 2 patients who underwent total remnant pancreatectomy within 3 months after PD, and 1 patient who had NAFLD preoperatively, leaving a total of 120 patients who were analyzed. Postoperative pancreatic enzyme supplements were not administered routinely, except to patients with diarrhea. When pancreatic enzyme supplementation therapy was administered, the start and end dates of its administration were recorded. Changes of the brand of drug and quantity in the pancreatic enzyme drug administered were also noted. Supplementation therapy was prescribed to treat postoperative diarrhea or at each surgeon's discretion, but we were unable to use the medical records to differentiate diarrhea from steatorrhea. When pancreatic enzyme supplementation therapy was started during the early postoperative period and before NAFLD was diagnosed, we considered that it was administered prophylactically for NAFLD after PD, even if the supplement was administered to treat diarrhea. When pancreatic enzyme supplementation began after NAFLD was diagnosed, it was considered to be a therapeutic administration. If a patient was already receiving prophylactic supplementation, a change in the drug administered or an increase in dosage was considered to be therapeutic supplementation. The administration of perioperative radiation and/or chemotherapy was recorded and included notes on their regimens and durations. The volume of pancreatic juice output through the external MPD stent was measured every day until stent removal. We reviewed the clinical records and all of the CT images for each patient retrospectively.
Diagnosis of the occurrence of and recovery from NAFLD after PD. All patients underwent preoperative and postoperative abdominal CTs. Preoperative dynamic CTs were performed and were saved as thin-slice (1-3 mm) images. The post-PD CTs were performed within 3 months on 85.0% (102/120) of the patients, within 6 months on 95.8% (115/120) of the patients, and within 1 year on 100% of the patients (120/120). Routine follow-up intervals for CT were once every 6 months or once per year. We reviewed all preoperative CTs and as many of the postoperative follow-up CTs as possible. The CT images obtained during the terminal stages of malignant disease were excluded from the assessments of NAFLD after PD. The CT attenuation of the liver was measured at 3 locations on unenhanced images. We calculated the mean CT attenuation value for the liver and defined a hepatic CT value of <40 Hounsfield units (HU) as NAFLD. 22 An increase of the hepatic CT attenuation value was considered to be a "recovery." Normalization of the liver CT attenuation value by $40 HU was considered to be a "full recovery," and an increase of the liver CT attenuation value of <40 HU was considered a "partial recovery."
Measurements of the pancreas and pancreatic volumetry. Using the thin-slice CT images obtained preoperatively, the preoperative pancreatic volume was measured with a volume analyzer (Synapse Vincent; Fujifilm Medical Co, Ltd, Tokyo, Japan). Detectable tumors, cysts, the MPD, and the common bile duct were eliminated from the pancreatic volume in the 3-dimensional images. The volume of the remnant pancreas was calculated based on the pancreas' dividing line (supplementary Fig 1, 
online version only).
Remnant pancreatic rate was calculated as [Volume of remnant pancreas]/[Total volume of the pancreas]. The pancreatic thickness and the diameter of the MPD were measured in all pre-and postoperative CT images. The pancreatic thickness was measured at the midpoint of the remnant pancreas after PD. The pancreas' dividing line was confirmed during the reviews of the surgical records. The thickness of the pancreatic parenchyma was calculated as the "pancreatic thickness" minus the "diameter of the MPD." A change in the thickness of the pancreatic parenchyma was assessed using ratios derived from the pre-and postoperative values.
Evaluation of factors affecting the risk of and recovery from NAFLD after PD. We evaluated the pre-, intra-, and postoperative factors that might be associated with the development of or recovery from NAFLD after PD. The preoperative factors included age, sex, body mass index (BMI), preoperative jaundice, diabetes mellitus, hyperlipidemia, chronic pancreatitis, the diagnosis, the mean hepatic CT attenuation value, the pancreatic volume, the diameter of the MPD, the thickness of the pancreatic parenchyma, and laboratory parameters that included the hemoglobin, platelet count, serum levels of glycated hemoglobin, total protein, albumin, total cholesterol, triglyceride, C-reactive protein, amylase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), carcinoembryonic antigen, and carbohydrate antigen 19-9 levels. The intraoperative factors included the resection and reconstruction methods, resection of the nerve plexus around the superior mesenteric artery, the operative time, and the volume of blood lost. The postoperative factors included the volume of the pancreatic juice output, complications based on the Clavien-Dindo classification, 23 the presence of pancreatic fistulae based on the International Study Group on Pancreatic Fistula criteria, 24 the duration of the presence of the MPD stent, the presence of postoperative diarrhea and timing, the use of anti-diarrheal therapy, changes in body weight at 2 and 4 weeks postoperatively, the laboratory parameters, and all of the CT parameters, which were assessed until the patient died or until the end of the follow-up period at our institution.
Risk scoring system for NAFLD after PD. Based on the results of a multivariable analysis of the risk factors for NAFLD, we developed a risk scoring system to estimate the possibility of developing NAFLD after PD. Each score was determined based on the odds ratios (ORs) of the independent risk factors. The cut-off points were chosen based on the occurrence rates of NAFLD in all patients. The patients were categorized into "low-risk" and "highrisk" groups. The occurrence of NAFLD was compared using a log-rank test. The 90% confidence intervals (CIs) of the ORs were calculated using the bootstrap method.
Statistical analyses. Student t test or Welch t test was used to analyze the continuous variables based on the results from the F-test. The v 2 test or Fisher exact test was used to analyze the categorical variables based on a minimum expectation of <5. All of the continuous variables' cut-off points were determined using receiver operating characteristic (ROC) curves. Univariate and multivariable logistic regression analyses were used to identify the risk factors associated with the development of NAFLD after PD. All of the factors that were statistically significant in the univariate analysis were subjected to multivariable logistic regression analysis. The factors that were associated with recovery from NAFLD were also analyzed using univariate and multivariable logistic regression analyses. Survival and occurrence analyses were conducted using the Kaplan-Meier method, and the results were compared using the log-rank test. All of the statistical analyses were performed using IBM SPSS Statistics for Windows, version 23.0 (IBM Corporation, Armonk, NY).
RESULTS
Patient characteristics. The mean age was 67.6 years, and the male-to-female ratio was 82:38. The indications for PD included pancreatic ductal adenocarcinoma (n = 43, 35.8%), ampullary carcinoma (n = 23, 19.2%), intraductal papillary mucinous neoplasm (n = 19, 15.8%), bile duct carcinoma (n = 13, 10.8%), ampullary adenoma (n = 3, 2.5%), chronic pancreatitis (n = 3, 2.5%), duodenal carcinoma (n = 3, 2.5%), autoimmune pancreatitis (n = 2, 1.7%), and others (n = 11, 9.2%). Conventional PD was performed in 19 patients, pylorus-preserving PD in 26, and subtotal stomach-preserving PD in 75, with an Imanaga reconstruction in 27, and a modified Child reconstruction in 93. Six (5%) patients received postoperative radiation therapy, and 23 (19.2%) received adjuvant chemotherapy, comprising S-1 in 10, gemcitabine in 9, tegafur/uracil in 3, and imatinib in 1. The mean duration of the observation period was 34.6 months (median 27.8, range 1.3-118.0 months).
Occurrence rate of NAFLD. De novo NAFLD was diagnosed in 45 of 120 (37.5%) patients. Prophylactic pancreatic enzyme supplementation therapy was prescribed to 41 out of 120 (34.2%) patients, and NAFLD was diagnosed in 11 out of 41 (27%) of these patients. NAFLD was diagnosed in 34 of the 79 (43%) patients who did not receive prophylactic pancreatic enzyme supplementation therapy (P = .082).
Time until diagnosis of NAFLD after PD. The mean time to a diagnosis of NAFLD was 9.1 ± 10.7 months after PD (median 5.5, range 0.36-57.1 months), and 77.8% of the patients were diagnosed with NAFLD within 12 months of the operation. The female patients were diagnosed with NAFLD earlier (156 ± 109 days) than the male patients (380 ± 407 days, P = .018). The Kaplan-Meier curves are shown in Fig 1. One patient did not develop NAFLD until 57.1 months after operation. Although according to CT images, this patient had not developed NAFLD at 51.9 months postoperatively and had received pancreatic enzyme supplementation therapy until 52 months postoperatively, NAFLD occurred after supplementation ceased.
Outcomes of patients with NAFLD after PD. Of the 45 patients diagnosed with NAFLD, 6 received therapeutic pancreatic enzyme supplementation after diagnosis. All of these patients showed some extent of recovery (100%), and 4 patients had full recoveries. The therapeutic drug administered was delayed-release pancrelipase (LipaCreon; Eisai Co, Ltd, Tokyo, Japan). Full-dose pancreatic enzyme supplementation therapy (1,800 mg/day) was prescribed to 4 patients, all of whom showed full recoveries. The other 2 patients, who were administered half-dose pancreatic enzyme supplementation therapy, showed partial recoveries. Of the 39 patients who did not receive therapeutic pancreatic enzyme supplementation, 21 showed recoveries (54%) and 20 showed full recoveries (51%). Among the patients who recovered from NAFLD spontaneously, 55% recovered within 6 months, and 90% recovered within 1 year. The recovery rate tended to be greater in patients who had received therapeutic pancreatic enzyme supplementation (100% vs 54%, P = .069). Two NAFLD patients who did not receive pancreatic enzyme supplementation therapy died of liver failure. The Kaplan-Meier curves are shown in Fig 2. The occurrence of NAFLD did not affect prognosis (P = .716).
Perioperative characteristics of the patients who developed NAFLD after PD. Table I shows the pre-, intra-, and postoperative characteristics of the patients in relation to the development of NAFLD after PD. More detailed data are presented in supplementary Table I (online version only). In relation to the preoperative factors, the group who developed NAFLD after PD had greater BMI (P = .013). The proportion of females was greater in the group who developed NAFLD after PD (47% vs 23%, P = .006), and the group who developed NAFLD after PD had a greater prevalence of hyperlipidemia after PD (20% vs 5%, P = .017). The patients who developed NAFLD after PD had lower platelet counts, greater glycated hemoglobin levels, and smaller preoperative pancreatic volumes (P # .05 each). In relation to the intraoperative factors, the operative time was greater; the remnant pancreas was smaller in volume; and the remnant pancreatic rate (remnant pancreatic rate = [volume of the remnant pancreas] / [preoperative total volume of the pancreas]) was less in the group who developed NAFLD (P # .04 each). In relation to the resection and reconstruction methods, the differences between the patients who developed NAFLD after PD and those who did not were insignificant. In relation to the postoperative factors, the outputs of pancreatic juice volumes on postoperative days (PODs) 7 and 14 were less in the patients who developed NAFLD. Regarding the laboratory assessments performed within 1 month after PD, only the serum amylase level on POD 14 was less in the patients who developed NAFLD. The postoperative serum amylase level was generally less in the patients who developed NAFLD.
Influence of NAFLD on the nutritional status and pancreatic CT images. Table II compares the periods "during NAFLD" and "during non-NAFLD" to the parameters from the CT images and the evaluations at the same time points. The liver CT value was less during NAFLD. The pancreatic parenchyma was thinner during NAFLD (P < .001). Although the differences were small, the total protein, albumin, total cholesterol, and triglyceride levels were significantly less during NAFLD. The serum amylase level was less, and the AST and ALT levels were greater during NAFLD (P # .05).
Risk factors for the de novo development of NAFLD after PD. Table III presents Malignancy, radiation therapy, and adjuvant chemotherapy did not show any significant differences between those who developed NAFLD after PD and those who did not (P $ .05 each). We used all of the factors that were significant in the univariate analysis in the multivariable logistic regression analysis.
The multivariable logistic regression analysis identified the following as independent risk factors for the development of NAFLD after PD: high BMI (OR 12.2, P = .008), small pancreatic volume (OR 9.85, P = .012), long operative time (OR 6.35, P = .023), and high AST/ALT ratio (OR 10.1, P = .008). Risk scoring system. Risk scores were computed for each independent risk factor based on the results of the multivariable logistic regression analysis. A long operative time, which had the least OR of 6.4, was assigned 1 point. The factors that had ORs that were close to 10, namely, small pancreatic volume and high AST/ALT ratio, were assigned 2 points, and high BMI, which had the greatest OR of 12.2, was assigned 3 points (Table III) . Each score was applied to our data retrospectively, and based on a total score of 8, the cohort was divided into 2 groups, namely, "low-risk" (total score #3) and "high-risk" (total score $4) groups. The cut-off point was chosen based on the NAFLD occurrence rate (n = 120, 37.5%), and the NAFLD occurrence rates were 20.6% (n = 63) in the low-risk group and 56.1% (n = 57) in the high-risk group (P < .0001). The OR was 5.6 (95% CI, 2.3-23.3). The Kaplan-Meier curves are shown in Fig 3. Factors associated with recovery from NAFLD after PD. Table IV shows the results from the univariate and multivariable logistic regression analyses of recovery from NAFLD after PD. The cut-off points were chosen using an ROC curve for a full recovery as the response variable. The univariate analysis of the factors associated with recovery from NAFLD after PD showed that a thinner preoperative MPD diameter, lower serum amylase levels on PODs 14 and 28, a greater minimum hepatic CT value, and a late diagnosis time were significantly associated with recovery from NAFLD after PD. The multivariable logistic regression analysis determined that a smaller diameter preoperative MPD of <2.3 mm (OR 7.6, P = .036), a greater minimum liver CT value of $14.2 HU (OR 17.5, P = .023), and a lesser serum amylase level on POD 28 of <43 IU/L (OR 18.3, P = .023) were independently associated with recovery from NAFLD after PD. A lesser preoperative hemoglobin level of <13.5 g/dL (OR 6.7, P = .033) and a greater minimum hepatic CT value of $14.2 HU (OR 11.6, P = .033) were independently associated with a full recovery from NAFLD after PD.
DISCUSSION
The incidence of NAFLD after PD has been reported to range from 7.8-40%, [4] [5] [6] [7] [8] [9] [10] 25, 26 and such a broad range could be associated with the different durations of the observation periods, which ranged from 3.2-21 months. In the current study, NAFLD occurred in 37.5% of the patients who underwent PD, which is within the range reported in previous publications; however, the time to the onset of NAFLD in some of our patients was greater than we anticipated. Indeed, 1 patient developed NAFLD 58 months after PD, and 22% of the patients were diagnosed with NAFLD more than 12 months after PD. These findings suggest that prolonged follow up is required for patients who have undergone PD. NAFLD generally signifies overnutrition, but NAFLD after PD has different clinical features. Our data showed that the nutritional status of the patients who developed NAFLD after PD was poor, as determined by lower total protein, albumin, total cholesterol, and triglyceride levels. Additionally, the factors that are considered to reflect pancreatic function---namely, the thickness of the pancreatic parenchyma and the serum amylase level---were also significantly less. These results are consistent with data that suggest that the main concern associated with the development of NAFLD after PD is pancreatic dysfunction, which affects patients' digestion and absorption. Hence, we wondered if pancreatic exocrine dysfunction was the only risk factor associated with the development of NAFLD after PD.
Many different types of risk factors associated with the development of NAFLD after PD have been reported, [5] [6] [7] 9, 10, 25, 26 but the studies from which these risk factors were reported had short observation periods or small numbers of patients with NAFLD, and few studies included multivariable regression analyses. Previous publications that describe the development of NAFLD after PD are summarized in Table V . Kato et al 7 showed that the presence of pancreatic adenocarcinoma, the pancreatic resection line, and diarrhea were independent risk factors associated with the development of NAFLD after PD, while Tanaka et al 5 reported that cancer of the pancreatic head was a significant risk factor associated with the development of NAFLD after PD. Song et al 10 reported that the presence of a pancreatic fistula and an external pancreatic duct stent were significant factors associated with the development of NAFLD after PD. Moreover, Sato et al 9 reported that age (younger), sex (female), small remnant pancreatic volume, and infection on PODs 7-28 were significant risk factors associated with the development of NAFLD after PD. In our study, the multivariable logistic regression analysis determined 4 independent risk factors associated with the development of NAFLD after PD. Although these factors have not been described previously, some of the risks determined by the present study's univariate analysis to be associated with the development of NAFLD after PD have been described previously. A high BMI is generally considered a risk factor for typical NAFLD, and we found that it was also a risk factor for the development of NAFLD after PD. Being female was a significant risk factor for the development of NAFLD after PD in our univariate analysis, and it was determined to be a risk factor in a previous study. 9 The results from the current study also showed that the female patients developed NAFLD earlier than the male patients; thus, female patients should be followed more carefully than male patients. The preoperative pancreatic volume was an independent risk factor for the development of NAFLD after PD, and other measured pancreatic values---namely, the thickness of the pancreatic parenchyma, the remnant pancreatic volume, the remnant pancreatic rate, and atrophy of the pancreatic parenchyma---were significant factors in the univariate analysis. We consider that all these factors reflect the poor nutritional condition of a patient post-PD, because they will predict a low level of pancreatic exocrine function postoperatively. In our institution, all patients undergo the placement of an external pancreatic duct stent, and the output volumes of the pancreatic juice are measured until the stent is withdrawn. Although dependent on the concentrations of the digestive enzymes, a low volume of output should reflect a low level of pancreatic exocrine function. Patients with pancreatic fistulae should have some pancreatic exocrine function, but pancreatic fistulae may not occur in patients whose pancreatic exocrine function has been exhausted. The univariate analysis carried out in the present study showed that the absence of pancreatic fistulae and lesser serum amylase level were risk factors associated with NAFLD development, which supports these concepts.
It seems that pancreatic enzyme replacement has become standard postoperative care for post-PD patients in some institutions, 4, 5, [8] [9] [10] 27 but as far as we are aware, these drugs have not been administered generally to pancreatectomized patients until recently. Used as a prophylactic supplement before the occurrence of diarrhea, pancreatic enzyme replacement therapy was only routinely administered to patients who had undergone total pancreatectomy, but it was prescribed occasionally at the surgeon's discretion. These prescriptions did not target NAFLD, and we defined all pancreatic enzyme supplementations as prevention or therapy for NAFLD. In our study, only 34.2% of the patients (41/120) were given pancreatic enzyme replacement therapy that began shortly after PD and before NAFLD developed. The patients who received pancreatic enzyme replacement therapy had a lesser rate of NAFLD compared with those who did not receive enzyme replacement therapy (27% vs 43%, P = .082); therefore, we suggest that prophylactic supplementation therapy had a measurable effect. Nevertheless, we think that pancreatic enzyme replacement therapy is not always necessary for patients who undergo PD, because the patients in our study who did not receive therapeutic supplementation had a recovery rate of >50%. Furthermore, in most of the recent studies, pancreatic enzyme supplementation therapy was administered to patients before they developed NAFLD, and the NAFLD occurrence rates did not differ greatly from the rate in the current study.
Some investigators have described the therapeutic efficacy of pancreatic enzyme supplementation for NAFLD. Tanaka et al 5 prescribed another type of pancreatic enzyme supplement to patients who developed NAFLD after PD in addition to the supplement that they were already receiving, and they found that it significantly improved the liver/ spleen ratio, patient weight, the BMI, and the serum levels of albumin and cholinesterase. Nagai et al 4 reported a prospective study in which the administration of pancrelipase improved the liver/spleen ratio in patients with NAFLD after PD. Our data also showed the therapeutic benefit of pancrelipase. The patients who received pancrelipase had better recovery rates than those who did not receive therapy (100% vs 54%, P = .069), and all of the patients who were prescribed full-dose pancrelipase showed full recoveries. Given the results from previous studies and those from our own study, we considered that it would be valuable to identify the patients who actually require pancreatic enzyme supplementation therapy. To accomplish this, an analysis of recovery from NAFLD was essential.
As far as we are aware, this is the first report to describe the factors associated with recovery from NAFLD after PD. Our study, however, was a retrospective study that involved only 45 patients who developed NAFLD after PD; hence, we could detect only a few factors that were predictive of recovery from NAFLD---namely, a thinner preoperative MPD, a lesser serum amylase level, and a greater minimum hepatic CT value. Therefore, based on our results, when patients develop NAFLD after PD, we should pay particular attention to those who do not have these recovery factors. We found that a low serum amylase level was a common factor associated with the risk of developing NAFLD after PD, and it affected recovery time as well. A decrease in the exocrine function of the pancreas is among the causes of NAFLD after PD. We consider that if the main cause of NAFLD after PD is a decrease in the exocrine function of the pancreas, patients could easier develop NAFLD. Still, recovery will be easier in patients with low serum amylase levels than in those who have high serum amylase levels, because the NAFLD in patients with high serum amylase levels might not only be a consequence of decreased pancreatic function; it could be associated with other factors, including chemotherapy, radiation therapy, the patient's general condition, or other organ dysfunction. In this study, 2 patients died from liver failure. These patients developed NAFLD after PD, and pancreatic enzyme supplements were not being administered. When our risk scoring system was applied to these patients, both belonged to the high-risk group. In relation to the recovery factors, 1 patient had only 1 of the 3 factors associated with recovery, while the other patient did not have any of the factors that are associated with recovery. Hence, based on these results and our experience of liver failure, we recommend that if a patient has some risk factors or is considered high risk, prophylactic pancreatic enzyme supplementation therapy should be administered, and our scoring system can assist with such decision-making. If a patient develops NAFLD and does not have any of the recovery factors or has 1 factor only, therapeutic pancreatic enzyme supplements should be administered. When patients are receiving pancreatic enzyme supplements, increasing the dose or changing the drug should be effective. We consider that it is difficult to assess pancreatic insufficiency from the clinical symptoms or evaluations of the blood alone, and findings from CT of the pancreas can assist in its assessment. Although our study comprises the largest cohort of patients with NAFLD after PD and it has the greatest observation period, the limitations of this study include its retrospective design, the nonstandardized protocol for pancreatic enzyme supplementation, and the small sample size. More large-scale studies and/or prospective research are needed to clarify these clinical questions and to derive robust recommendations; studies may also evaluate the use of pancreatic enzyme supplementation routinely in all patients after PD.
In conclusion, surgeons should follow the postoperative hepatic CT values of any patient who has undergone PD even if the patient is receiving pancreatic enzyme supplementation therapy, and they should remember that NAFLD may develop years after PD. The occurrence of NAFLD in patients who have undergone PD requires longterm follow up, even for those patients who are receiving pancreatic enzyme supplementation therapy; however, about half of the patients will recover without the administration of any pancreatic enzyme drug. In the postoperative management of patients who have undergone PD, the administration of preventive supplementation therapy should be based on risk factors, and therapeutic supplementation should use the factors associated with recovery as reference points for decision making. We should continue to study the significance of therapeutic supplementation in patients following PD.
